SIRT Sierra Natl BK Tehachapi Calif (MM)

Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it will present two posters at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conferences from August 4 to August 9, 2007. The "Glucose Transporter Biology" poster will be presented in Snowmass Village, Colorado; and the "Obesity, Energy Balance & Disease" poster will be presented in Indian Wells, California. The data presented offer mechanistic insight on SIRT1 activation via resveratrol and via new chemical entities (NCEs), which are structurally unrelated to and significantly more potent than resveratrol, as demonstrated in pre-clinical studies. Data showing glucose lowering and improved insulin sensitivity with NCEs in multiple pre-clinical models of Type 2 Diabetes such as diet induced obesity model, ob/ob, and Zucker fa/fa, also will be presented. About Sirtris Pharmaceuticals Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, Sirtris Pharmaceuticals, its product candidates and those candidates� clinical potential. These forward-looking statements about future expectations, plans and prospects of Sirtris Pharmaceuticals involve significant risks, uncertainties and assumptions, including risks related to the lack of results that would provide a basis for predicting whether any of the Company�s product candidates will be safe or effective, or receive regulatory approval, the possibility that results of pre-clinical studies are not necessarily predictive of clinical trial results, the Company's potential inability to initiate and complete pre-clinical studies and clinical trials for its product candidates, the fact that none of the Company's product candidates has received regulatory approvals, the fact that none of the results from pre-clinical studies may be achieved in clinical studies, the potential inability of the�Company to gain market acceptance of the Company's product candidates, and those other risks factors�that can be found in the�Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those Sirtris Pharmaceuticals contemplated by these forward-looking statements. Sirtris Pharmaceuticals does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.